Drugs · acquisition-cost intelligence
AZMIRO
testosterone cypionate· ingredient testosterone3-oxoandrosten (4) derivatives· TESTOSTERONE CYPIONATE 200 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$11.19
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other testosterone products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| testosterone | $0.45945 | −$10.73 |
| testosterone | $0.61771 | −$10.58 |
| AndroGel | $0.65670 | −$10.54 |
| Testosterone | $0.91844 | −$10.28 |
| Testim | $2.24 | −$8.96 |
| testosterone | $2.97 | −$8.23 |
| Depo-Testosterone | $5.41 | −$5.78 |
| testosterone cypionate | $11.19 | +$0.00000 |
Medicare Part D coverage · CY2026
On 309 plan formularies · typical tier 2
Prior auth 69% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.